AU2008289522A1 - Treatment of lung cancer - Google Patents

Treatment of lung cancer Download PDF

Info

Publication number
AU2008289522A1
AU2008289522A1 AU2008289522A AU2008289522A AU2008289522A1 AU 2008289522 A1 AU2008289522 A1 AU 2008289522A1 AU 2008289522 A AU2008289522 A AU 2008289522A AU 2008289522 A AU2008289522 A AU 2008289522A AU 2008289522 A1 AU2008289522 A1 AU 2008289522A1
Authority
AU
Australia
Prior art keywords
scv
group
day
tumor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008289522A
Other languages
English (en)
Inventor
Cynthia W. Tuthill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of AU2008289522A1 publication Critical patent/AU2008289522A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2008289522A 2007-08-23 2008-08-21 Treatment of lung cancer Abandoned AU2008289522A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95753007P 2007-08-23 2007-08-23
US60/957,530 2007-08-23
PCT/US2008/009932 WO2009025830A1 (en) 2007-08-23 2008-08-21 Treatment of lung cancer

Publications (1)

Publication Number Publication Date
AU2008289522A1 true AU2008289522A1 (en) 2009-02-26

Family

ID=40378469

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008289522A Abandoned AU2008289522A1 (en) 2007-08-23 2008-08-21 Treatment of lung cancer

Country Status (14)

Country Link
US (1) US20110189305A1 (enExample)
EP (1) EP2192835A4 (enExample)
JP (1) JP2010536854A (enExample)
KR (1) KR20100063078A (enExample)
CN (1) CN101842009A (enExample)
AU (1) AU2008289522A1 (enExample)
BR (1) BRPI0815772A2 (enExample)
CA (1) CA2697261A1 (enExample)
EA (1) EA201070295A1 (enExample)
MX (1) MX2010002046A (enExample)
NZ (1) NZ584065A (enExample)
UA (1) UA98508C2 (enExample)
WO (1) WO2009025830A1 (enExample)
ZA (1) ZA201001876B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96980C2 (ru) 2007-02-13 2011-12-26 Сайклон Фармасютикалс, Инк. Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки
RU2519738C2 (ru) * 2011-12-12 2014-06-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации Способ лечения рака легкого

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902790A (en) * 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
RU2141483C1 (ru) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
RU2229892C2 (ru) * 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких

Also Published As

Publication number Publication date
NZ584065A (en) 2012-03-30
WO2009025830A1 (en) 2009-02-26
JP2010536854A (ja) 2010-12-02
CN101842009A (zh) 2010-09-22
ZA201001876B (en) 2010-11-24
US20110189305A1 (en) 2011-08-04
EP2192835A4 (en) 2010-11-10
UA98508C2 (ru) 2012-05-25
MX2010002046A (es) 2010-05-03
EA201070295A1 (ru) 2010-10-29
KR20100063078A (ko) 2010-06-10
EP2192835A1 (en) 2010-06-09
CA2697261A1 (en) 2009-02-26
BRPI0815772A2 (pt) 2014-09-30

Similar Documents

Publication Publication Date Title
EP2786756B1 (en) Combination therapy with a topoisomerase inhibitor
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
Peng et al. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer
US20120316189A1 (en) Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients diagnosed or undiagnosed respiratory illness
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
McGregor et al. Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors
WO2009138509A1 (en) Multiple myeloma treatments
KR102664243B1 (ko) 암 환자의 치료에 유용한 오줌의 알칼리제
AU2008289522A1 (en) Treatment of lung cancer
AU644684B2 (en) Antineoplastic effect potentiator and antineoplastic agent
Shinohara et al. Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck
KR20140144215A (ko) 오로라 키나제 저해제를 사용하는 암 치료 방법
CN117942345A (zh) 一种arv-825分子配体治疗nut癌方法
CN102946878A (zh) 前列腺癌的治疗方法
US20240366637A1 (en) Compounds inhibiting the synergistic carsinogenic effect of heavy metals in the presence of other carcinogens for use in the treatment of cancer
MXPA06014477A (es) Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer.
Anaya et al. Magnesium Infusion for Analgesia in Critically Injured Trauma Patients: A Randomized Controlled Trial
RU2045950C1 (ru) Способ лечения туберкулеза мочевой системы
WO2003059355A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
Fasih et al. Metformin as a Radiosensitizer in Pancreatic Cancer Cells
KR20190124950A (ko) Pfi-3를 포함하는 폐암 또는 대장암의 예방 또는 치료용 조성물
Abbas et al. HISTONE DEACETYLASE (HDAC1) AND HISTONE ACETYLTRANSFERASE (CBP/P300) IN THE PATHOGENESIS OF PROSTATE CANCER: 1104
Hasegawa et al. A COMBINATION OF S-1 AND DOCETAXEL ACTS SYNERGISTICALLY BY MODULATING METABOLIC ENZYME AND NUCLEAR FACTOR-KAPPA B ACTIVITY IN A HUMAN PROSTATE CANCER CELL LINE.: 1103
HK1202423B (en) Combination therapy with a topoisomerase inhibitor
HK1202419B (en) Combination therapy with a mitotic inhibitor

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period